Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

ents currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, next-generation rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-lookin
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015 Konica Minolta ... Computed Radiography (CR) system, designed to deliver enterprise level ... utilizing the same Control Station as the Konica Minolta ... with an upgrade path from CR to DR. The ... to help improve workflow with unparalleled reliability and high ...
(Date:9/1/2015)... VEGAS , Sept. 1, 2015  Dr. ... DigiPath Labs , the cannabis testing subsidiary of DigiPath, ... Patients Group about the lack of consistency in ... the online resource for medical cannabis information, she explained ... patients because their lack of uniform requirements makes standardization ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
... California, June 6 , - "ADVANCE Results ... the world,s largest ever study of diabetes treatments,show ... release,gliclazide and other drugs as required, protects patients ... treatment reduces,the risk of kidney disease by one-fifth. ...
Cached Medicine Technology:New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:9/1/2015)... Seattle, WA (PRWEB) , ... September 01, 2015 , ... ... despite increasing awareness of societal issues and needs. Money for Good 2015, released today ... for solving it. There’s an annual potential to mobilize up to $22B in new ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to have ... Surgery, according to a new survey that also offers insight on why that ... – which reflects views on cosmetic medical treatments and ratings for 10 specific ...
(Date:9/1/2015)... Fairfax, VA (PRWEB) , ... September 01, 2015 ... ... the Mane Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s ... modern technology, and beauty tools. In her upcoming city-to-city tour, Ellis will be ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit ... and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 years, ... million for programs and services designed to support patients and their families during their ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit Inc., a leading ... the FirstSpirit Content Management System with new capabilities and enhancements designed to support ... companies will be well on their way to achieving digital transformation with less ...
Breaking Medicine News(10 mins):Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... of the disease was found to have been cut to half ... The study involving about 6,000 patients over six years in many ... among patients given the drugs. // , The drugs ... strokes and heart attacks and consequently deaths. The drugs cost only ...
... many grueling and expensive options to explore for women who ... ,According to an article from the San Francisco Chronicle, ... been through the other options. They usually face multiple problems ... a certain number of eggs, hundreds are lost with each ...
... programme helps people with chronic illness.Researchers at the ... in Carolina, USA, offered 104 patients with chronic ... eight weeks. ,The patients, who suffered from ... gastrointestinal problems, and high blood pressure, reported dramatic ...
... effects on the heart among the young and old.There ... diameter of less than ten micrometres. These can cause ... circulation, especially in people with pre-existing disease. ... University now reveals that the adverse effects of pollution ...
... for a year at a time can keep lungs ... to American researchers. At the University of Ohahio, Dr.Margit ... ,They studied more than 1,000 Finnish participants in ... had quit permanently, those who had quit intermittently, and ...
... vegans that are very low in animal products can be ... in turn strengthen teeth. ,Dr.Ludwig Leibsohn, faculty in ... a prolonged time can be at risk of periodontal disease. ... D, becoming more susceptible to decay."// ,Deficiencies in ...
Cached Medicine News:
... clinical and economic issues of cerclage wiring, ... to maximize tension control while minimizing invasion ... efficient instrumentation with a simple technique. , ... indicated for general orthopaedic trauma surgery involving: ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... aggressive innovations have become the accepted standard ... The AML Total Hip System was ... and effectively meet the needs for biological ... greater than 15 years of documented clinical ...
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Medicine Products: